2025
SJR Q1
JCR Q3 · 2,9
3 eşleşen makale
SCIE
Dergi ayrıntısı
Journal of Immunotherapy
- Yayıncı
- Lippincott Williams and Wilkins
- Ülke
- United States · Northern America
- Tür
- journal
- ISSN
-
1524955715374513
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 1,088
- Quartile Q1
- H-Index 111
- Atıf/yayın 2,75
- Doküman (3y) 145
- Atıf (3y) 426
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 2,9
- 5Y JIF 3,4
- JCI 0,67
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Cancer Research Q2
- Immunology Q2
- Immunology and Allergy Q2
- Pharmacology Q1
Alanlar
- Biochemistry, Genetics and Molecular Biology
- Immunology and Microbiology
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS kategorileri
- Oncology | Immunology | Medicine, Research & Experimental
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q3 | 1,088 | 2,9 | 3,4 | 0,67 | Q2 | 111 |
| 2024 | Q1 | Q2 | 1,203 | 2,9 | 3,4 | 0,67 | Q2 | 108 |
| 2023 | Q1 | Q2 | 1,263 | 3,2 | 3,6 | 0,83 | Q2 | 108 |
| 2022 | Q1 | Q2 | 1,397 | 3,9 | 4,5 | 0,85 | Q2 | 108 |
| 2021 | Q1 | Q2 | 1,182 | 4,9 | 4,6 | 0,96 | Q2 | 108 |
| 2020 | Q1 | Q2 | 1,805 | 4,5 | 4,7 | 1,07 | Q1 | 108 |
| 2019 | Q1 | Q2 | 1,557 | 4,1 | 3,7 | 1,12 | Q1 | 108 |
| 2018 | — | Q2 | — | 3,5 | 4 | 1,24 | Q1 | — |
| 2017 | Q1 | Q2 | 1,373 | 3,8 | 4 | 1,13 | Q1 | 108 |
| 2016 | Q1 | Q1 | 2,11 | 3,9 | 4 | — | — | 108 |
| 2015 | Q1 | Q1 | 2,192 | 3,7 | 3,6 | — | — | 108 |
| 2014 | Q1 | Q1 | 1,73 | 4 | 3,5 | — | — | 108 |
| 2013 | Q1 | Q2 | 1,802 | 3,4 | 3,1 | — | — | 108 |
| 2012 | Q1 | Q2 | 1,497 | 3,5 | 3,1 | — | — | 108 |
| 2011 | Q1 | Q2 | 1,466 | 3,3 | 3,2 | — | — | 108 |
| 2010 | Q1 | Q1 | 1,784 | 3,6 | 3,8 | — | — | 108 |
| 2009 | — | Q2 | — | 3,2 | 3,4 | — | — | — |
| 2008 | — | Q1 | — | 3,7 | 3,8 | — | — | — |
| 2007 | — | Q1 | — | 4,8 | 4,2 | — | — | — |
| 2006 | — | Q1 | — | 4,5 | — | — | — | — |
| 2005 | — | Q1 | — | 3,6 | — | — | — | — |
| 2004 | — | Q1 | — | 3,5 | — | — | — | — |
| 2003 | — | Q1 | — | 4 | — | — | — | — |
| 2002 | — | Q1 | — | 3,1 | — | — | — | — |
| 2001 | — | Q1 | — | 2,6 | — | — | — | — |
| 2000 | — | Q1 | — | 3 | — | — | — | — |
| 1999 | — | Q1 | — | 3,1 | — | — | — | — |
| 1998 | — | Q1 | — | 2,6 | — | — | — | — |
| 1997 | — | Q2 | — | 1,9 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | IMMUNOLOGY | SCIE | Q3 | Q3 | 116/183 |
| 2025 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q2 | 100/191 |
| 2025 | ONCOLOGY | SCIE | Q3 | Q2 | 175/333 |
| 2024 | IMMUNOLOGY | SCIE | Q3 | Q3 | 99/183 |
| 2024 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q2 | 93/195 |
| 2024 | ONCOLOGY | SCIE | Q2 | Q2 | 153/328 |
| 2023 | IMMUNOLOGY | SCIE | Q3 | Q2 | 99/181 |
| 2023 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q2 | 81/189 |
| 2023 | ONCOLOGY | SCIE | Q2 | Q2 | 129/322 |
| 2022 | IMMUNOLOGY | SCIE | Q3 | Q2 | 93/161 |
| 2022 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q2 | 70/136 |
| 2022 | ONCOLOGY | SCIE | Q2 | Q2 | 103/241 |
| 2021 | IMMUNOLOGY | SCIE | Q2 | Q2 | 79/162 |
| 2021 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q2 | 60/139 |
| 2021 | ONCOLOGY | SCIE | Q2 | Q2 | 96/245 |
| 2020 | IMMUNOLOGY | SCIE | Q2 | Q2 | 74/162 |
| 2020 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q2 | 62/140 |
| 2020 | ONCOLOGY | SCIE | Q2 | Q1 | 107/242 |
| 2019 | IMMUNOLOGY | SCIE | Q2 | Q1 | 58/159 |
| 2019 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q1 | 47/139 |
| 2019 | ONCOLOGY | SCIE | Q2 | Q1 | 85/244 |
| 2018 | IMMUNOLOGY | SCIE | Q2 | Q1 | 72/158 |
| 2018 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q1 | 55/136 |
| 2018 | ONCOLOGY | SCIE | Q2 | Q1 | 91/230 |
| 2017 | IMMUNOLOGY | SCIE | Q2 | Q1 | 55/155 |
| 2017 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | Q1 | 37/133 |
| 2017 | ONCOLOGY | SCIE | Q2 | Q1 | 80/223 |
| 2016 | IMMUNOLOGY | SCIE | Q2 | — | 47/151 |
| 2016 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 28/128 |
| 2016 | ONCOLOGY | SCIE | Q2 | — | 70/217 |
| 2015 | IMMUNOLOGY | SCIE | Q2 | — | 52/151 |
| 2015 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 29/124 |
| 2015 | ONCOLOGY | SCIE | Q2 | — | 67/213 |
| 2014 | IMMUNOLOGY | SCIE | Q2 | — | 40/148 |
| 2014 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 25/123 |
| 2014 | ONCOLOGY | SCIE | Q2 | — | 57/211 |
| 2013 | IMMUNOLOGY | SCIE | Q2 | — | 56/144 |
| 2013 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 36/124 |
| 2013 | ONCOLOGY | SCIE | Q2 | — | 73/203 |
| 2012 | IMMUNOLOGY | SCIE | Q2 | — | 49/137 |
| 2012 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 35/121 |
| 2012 | ONCOLOGY | SCIE | Q2 | — | 70/197 |
| 2011 | IMMUNOLOGY | SCIE | Q2 | — | 58/139 |
| 2011 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 33/112 |
| 2011 | ONCOLOGY | SCIE | Q2 | — | 70/196 |
| 2010 | IMMUNOLOGY | SCIE | Q2 | — | 42/134 |
| 2010 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 24/106 |
| 2010 | ONCOLOGY | SCIE | Q2 | — | 59/185 |
| 2009 | IMMUNOLOGY | SCIE | Q2 | — | 44/128 |
| 2009 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 24/93 |
| 2009 | ONCOLOGY | SCIE | Q2 | — | 58/166 |
| 2008 | IMMUNOLOGY | SCIE | Q2 | — | 32/121 |
| 2008 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 15/83 |
| 2008 | ONCOLOGY | SCIE | Q2 | — | 48/143 |
| 2007 | IMMUNOLOGY | SCIE | Q1 | — | 17/119 |
| 2007 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 8/81 |
| 2007 | ONCOLOGY | SCIE | Q1 | — | 24/132 |
| 2006 | IMMUNOLOGY | SCIE | Q1 | — | 23/117 |
| 2006 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 11/76 |
| 2006 | ONCOLOGY | SCIE | Q1 | — | 30/127 |
| 2005 | IMMUNOLOGY | SCIE | Q1 | — | 27/115 |
| 2005 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 14/72 |
| 2005 | ONCOLOGY | SCIE | Q2 | — | 40/123 |
| 2004 | IMMUNOLOGY | SCIE | Q2 | — | 28/111 |
| 2004 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 14/71 |
| 2004 | ONCOLOGY | SCIE | Q2 | — | 38/123 |
| 2003 | IMMUNOLOGY | SCIE | Q1 | — | 19/114 |
| 2003 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 11/72 |
| 2003 | ONCOLOGY | SCIE | Q1 | — | 25/120 |
| 2002 | IMMUNOLOGY | SCIE | Q1 | — | 29/119 |
| 2002 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 14/74 |
| 2002 | ONCOLOGY | SCIE | Q2 | — | 30/114 |
| 2001 | IMMUNOLOGY | SCIE | Q2 | — | 38/114 |
| 2001 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 17/75 |
| 2001 | ONCOLOGY | SCIE | Q2 | — | 40/107 |
| 2000 | IMMUNOLOGY | SCIE | Q1 | — | 25/116 |
| 2000 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 15/74 |
| 2000 | ONCOLOGY | SCIE | Q1 | — | 23/103 |
| 1999 | IMMUNOLOGY | SCIE | Q1 | — | 20/115 |
| 1999 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 16/76 |
| 1999 | ONCOLOGY | SCIE | Q1 | — | 21/105 |
| 1998 | IMMUNOLOGY | SCIE | Q1 | — | 28/120 |
| 1998 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 14/72 |
| 1998 | ONCOLOGY | SCIE | Q1 | — | 26/104 |
| 1997 | IMMUNOLOGY | SCIE | Q2 | — | 45/117 |
| 1997 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 18/61 |
| 1997 | ONCOLOGY | SCIE | Q2 | — | 33/102 |